Status:
RECRUITING
A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.
Lead Sponsor:
Aerin Medical
Conditions:
Nasal Airway Obstruction
Eligibility:
All Genders
22-85 years
Brief Summary
The purpose of this study is to compare the clinical outcomes of the VivAer procedure to functional rhinoplasty and septoplasty surgery for the treatment of nasal airway obstruction (NAO) to establish...
Detailed Description
The purpose of this study is to compare the clinical outcomes of the VivAer procedure to functional rhinoplasty and septoplasty surgery for the treatment of nasal airway obstruction (NAO) to establish...
Eligibility Criteria
Inclusion
- Age 22 to 85 years old (inclusively).
- Willing and able to provide consent.
- Willing and able to comply with the patient-specific requirements outlined in the study protocol.
- Has access to a mobile device, tablet, or computer with internet access and has access to an email address.
- Seeking treatment for NAO
- Has a NOSE Score of ≥55 indicating severe to extreme NAO.
- Have a positive modified Cottle maneuver.
- Planning either to undergo an intervention for NAO that includes one of the following as the primary approach:
- VivAer procedure for repair of nasal valve dysfunction (may include inferior turbinate and septal swell body as additional treated areas)
- Functional rhinoplasty surgery addressing the nasal valve and/or lateral nasal wall (may be combined with septoplasty with/without turbinoplasty performed alone or in combination).
- Septoplasty surgery with turbinate reduction.
Exclusion
- Has had nasal surgery (including sinus surgery) within the last 3 months.
- Has had a previous rhinoplasty (functional or cosmetic), septoplasty, inferior turbinate reduction, or VivAer procedure.
- Has extreme nasal pathology, a history of extreme nasal injuries, or an abnormal nasal condition (e.g. septal perforation or empty nose syndrome) that may be exacerbated by surgery.
- Has a medical condition(s) that may impair normal healing processes or be exacerbated by the stress of surgery.
- Has chronic rhinitis that is refractory to medications or rhinitis medicamentosa.
- Has poorly controlled chronic rhinosinusitis disease.
- Rhinoplasty is being performed primarily for cosmesis.
- Is receiving, planning to receive, or has received a Latera absorbable nasal implant at any time.
- Planning to have sinus or cosmetic surgery (e.g., functional endoscopic sinus surgery, cosmetic rhinoplasty) or a surgery involving the airway (e.g., hypoglossal nerve stimulation surgery, uvuloplasty, tonsillectomy, tongue base or soft palate interventions) within 6 months following enrollment.
- Is having an adjunctive surgical procedure performed with the primary NAO procedure (e.g. functional rhinoplasty with concha bullosa reduction, septoplasty with turbinate reduction performed with functional endoscopic sinus surgery)
Key Trial Info
Start Date :
February 28 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06922955
Start Date
February 28 2025
End Date
December 1 2027
Last Update
September 30 2025
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern Head and Neck Surgery
Alexander City, Alabama, United States, 35010
2
ExcelENT
Birmingham, Alabama, United States, 35244
3
North Alabama ENT
Huntsville, Alabama, United States, 35801
4
East Alabama ENT
Opelika, Alabama, United States, 36801